Especially for estrogen receptor-expressing (ER+) breast cancer and non-small cell lung cancer (NSCLC), there is ample evidence that Orai3 functions as an attractive therapeutic target in these pathogenic cell types. This evidence concerns the gene ORAI3 and breast cancer.